Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Adi Mory is active.

Publication


Featured researches published by Adi Mory.


American Journal of Human Genetics | 2012

Deleterious Mutations in LRBA Are Associated with a Syndrome of Immune Deficiency and Autoimmunity

Gabriela Lopez-Herrera; Giacomo Tampella; Qiang Pan-Hammarström; Peer Herholz; Claudia M. Trujillo-Vargas; Kanchan Phadwal; Anna Katharina Simon; Michel Moutschen; Amos Etzioni; Adi Mory; Izhak Srugo; Doron Melamed; Kjell Hultenby; Chonghai Liu; Manuela Baronio; Massimiliano Vitali; Pierre Philippet; Vinciane Dideberg; Asghar Aghamohammadi; Nima Rezaei; Victoria Enright; Likun Du; Ulrich Salzer; Hermann Eibel; Dietmar Pfeifer; Hendrik Veelken; Hans J. Stauss; Vassilios Lougaris; Alessandro Plebani; E. Michael Gertz

Most autosomal genetic causes of childhood-onset hypogammaglobulinemia are currently not well understood. Most affected individuals are simplex cases, but both autosomal-dominant and autosomal-recessive inheritance have been described. We performed genetic linkage analysis in consanguineous families affected by hypogammaglobulinemia. Four consanguineous families with childhood-onset humoral immune deficiency and features of autoimmunity shared genotype evidence for a linkage interval on chromosome 4q. Sequencing of positional candidate genes revealed that in each family, affected individuals had a distinct homozygous mutation in LRBA (lipopolysaccharide responsive beige-like anchor protein). All LRBA mutations segregated with the disease because homozygous individuals showed hypogammaglobulinemia and autoimmunity, whereas heterozygous individuals were healthy. These mutations were absent in healthy controls. Individuals with homozygous LRBA mutations had no LRBA, had disturbed B cell development, defective in vitro B cell activation, plasmablast formation, and immunoglobulin secretion, and had low proliferative responses. We conclude that mutations in LRBA cause an immune deficiency characterized by defects in B cell activation and autophagy and by susceptibility to apoptosis, all of which are associated with a clinical phenotype of hypogammaglobulinemia and autoimmunity.


Blood | 2008

Kindlin-3: a new gene involved in the pathogenesis of LAD-III

Adi Mory; Sara W. Feigelson; Nese Yarali; Sara Sebnem Kilic; Gulsum I. Bayhan; Ruth Gershoni-Baruch; Amos Etzioni; Ronen Alon

To the editor: Integrins constitute the major and largest cell adhesion receptor family. These heterodimers undergo dramatic allosteric conformational changes in response to various activation signals acting on their beta integrin subunit tails.[1][1] In hematopoietic cells, these events are


Blood | 2009

Loss of Kindlin-3 in LAD-III eliminates LFA-1 but not VLA-4 adhesiveness developed under shear flow conditions.

Eugenia Manevich-Mendelson; Sara W. Feigelson; Ronit Pasvolsky; Memet Aker; Valentin Grabovsky; Ziv Shulman; Sara Sebnem Kilic; Maria Alessandra Rosenthal-Allieri; Shifra Ben-Dor; Adi Mory; Alain Bernard; Markus Moser; Amos Etzioni; Ronen Alon

Leukocyte adhesion deficiency (LAD)-III is associated with homozygous stop codon mutations in Kindlin-3, the hematopoietic member of the Kindlin family of integrin coactivators. In addition, a subgroup of LAD-III patients has a homozygous splice junction mutation in and reduced expression of the Rap-1 guanine nucleotide exchange factor, CalDAG-GEFI (CDGI). In this study, we compared the adhesive properties of the leukocyte function-associated antigen-1 (LFA-1) and very late activation antigen-4 (VLA-4) integrins in both primary and activated leukocytes derived from these 2 LAD-III subgroups. Primary lymphocytes lacking both Kindlin-3 and CDGI lost all firm T-cell receptor-stimulated LFA-1 adhesiveness, in contrast to LAD-III lymphocytes deficient in Kindlin-3 alone. Effector T cells expanded from all tested LAD-III variants expressed normal CDGI, but lacked Kindlin-3. These Kindlin-3-null effector T cells exhibited total loss of inside-out LFA-1 activation by chemokine signals as well as abrogated intrinsic LFA-1 adhesiveness. Surprisingly, VLA-4 in Kindlin-3-null resting or effector lymphocytes retained intrinsic rolling adhesions to vascular cell adhesion molecule-1 and exhibited only partial defects in chemokine-stimulated adhesiveness to vascular cell adhesion molecule-1. Deletion of the putative beta(1) Kindlin-3 binding site also retained VLA-4 adhesiveness. Thus, our study provides the first evidence that Kindlin-3 is more critical to LFA-1 than to VLA-4-adhesive functions in human lymphocytes.


Journal of Clinical Immunology | 2010

Leukocyte Adhesion Deficiency Type II: Long-Term Follow-Up and Review of the Literature

Yael Gazit; Adi Mory; Amos Etzioni; Moshe Frydman; Oded Scheuerman; Ruth Gershoni-Baruch; Ben-Zion Garty

IntroductionLeukocyte adhesion deficiency (LAD) is a group of rare inherited disorders characterized by immune deficiency and peripheral neutrophilia. There are only seven reported cases of LAD type II worldwide, and no long-term follow-up data.Case ReportWe reviewed the medical file of a 20-year-old man with LAD II. Clinical characteristics included short stature, severe mental retardation, and autistic features. He had had no severe infections since infancy, and his current immunological status was stable. The last laboratory work-up revealed mild leukocytosis and neutrophilia. Genetic analysis of the Golgi GDP-fucose transporter (GFTP) sequence yielded a point mutation resulting in Y337C amino acid transition in the tenth transmembrane domain.ConclusionIn conclusion, in LAD II, the main clinical countenance shifts from frequent infections due to immunodeficiency in the early years to the metabolic consequences of the defect in fucose metabolism, i.e., retarded growth and mental retardation, in the later years. A novel mutation in the GFTP loci associated with LAD II is described.


Parkinsonism & Related Disorders | 2015

The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews

Efrat Dagan; Ilana Schlesinger; M. Ayoub; Adi Mory; M. Nassar; Alina Kurolap; J. Peretz-Aharon; Ruth Gershoni-Baruch

INTRODUCTION Parkinson disease is noted for its association with mutations in GBA and the p.G2019S mutation in LRRK2. This study aimed to evaluate the frequency of Ashkenazi founder mutations in sphingomyelin phosphodiesterase 1 (SMPD1) in Ashkenazi patients diagnosed with Parkinsons disease (PD); and their impact on PD phenotypic expression. SMPD1 underlies the lysosomal storage disease - Niemann-Pick. METHODS A case (n = 287) control (n = 400) study was undertaken. All patients underwent a physical, neurobehavioral and neurologic examination that incorporated the Unified Parkinsons Disease Rating Scale. Three founder SMPD1 Ashkenazi mutations (c.996delC (fsP330), p.L302P and p.R496L) were investigated in patients and controls, previously evaluated for carriage of founder mutations in GBA and the p.G2019S mutation in LRRK2. RESULTS Nine (3.1%) PD patients compared to two (0.5%) individuals from the control group were found to carry one of the three Ashkenazi SMPD1 founder mutations (p = 0.007). The overall clinical characteristics of PD patients carrying SMPD1 mutations were similar to those of PD patients with no mutations in SMPD1, GBA and LRRK2 (n = 189). CONCLUSION We maintain that disruptive mutations in SMPD1 constitute a risk factor for PD.


European Journal of Human Genetics | 2014

A missense mutation in ALDH1A3 causes isolated microphthalmia/anophthalmia in nine individuals from an inbred Muslim kindred

Adi Mory; Francesc X. Ruiz; Efrat Dagan; Evgenia Yakovtseva; Alina Kurolap; Xavier Parés; Jaume Farrés; Ruth Gershoni-Baruch

Nine affected individuals with isolated anophthalmia/microphthalmia from a large Muslim-inbred kindred were investigated. Assuming autosomal-recessive mode of inheritance, whole-genome linkage analysis, on DNA samples from four affected individuals, was undertaken. Homozygosity mapping techniques were employed and a 1.5-Mbp region, homozygous in all affected individuals, was delineated. The region contained nine genes, one of which, aldehyde dehydrogenase 1 (ALDH1A3), was a clear candidate. This gene seems to encode a key enzyme in the formation of a retinoic-acid gradient along the dorsoventral axis during an early eye development and the development of the olfactory system. Sanger sequence analysis revealed a missense mutation, causing a substitution of valine (Val) to methionine (Met) at position 71. Analyzing the p.Val71Met missense mutation using standard open access software (MutationTaster online, PolyPhen, SIFT/PROVEAN) predicts this variant to be damaging. Enzymatic activity, studied in vitro, showed no changes between the mutated and the wild-type ALDH1A3 protein.


The New England Journal of Medicine | 2017

Loss of CD55 in Eculizumab-Responsive Protein-Losing Enteropathy

Alina Kurolap; Orly Eshach-Adiv; Tova Hershkovitz; Tamar Paperna; Adi Mory; Danit Oz-Levi; Yaniv Zohar; Hanna Mandel; Judith Chezar; David Azoulay; Sarit Peleg; Elizabeth Half; Vered Yahalom; Lilach Finkel; Omer Weissbrod; Dan Geiger; Adi Tabib; Ron Shaoul; Daniella Magen; Lilach Bonstein; Dror Mevorach; Hagit Baris

CD55 (complement decay-accelerating factor) inhibits the alternative and classical arms of the complement pathway. Three patients with protein-losing enteropathy and a genetic variant predicted to result in loss of function of CD55 had a response to eculizumab.


American Journal of Human Genetics | 2016

Loss of Glycine Transporter 1 Causes a Subtype of Glycine Encephalopathy with Arthrogryposis and Mildly Elevated Cerebrospinal Fluid Glycine

Alina Kurolap; Anja Armbruster; Tova Hershkovitz; Katharina Hauf; Adi Mory; Tamar Paperna; Ewald Hannappel; Galit Tal; Yusif Nijem; Ella Sella; Muhammad Mahajnah; Anat Ilivitzki; Dov Hershkovitz; Nina Ekhilevitch; Hanna Mandel; Volker Eulenburg; Hagit N. Baris

Glycine is a major neurotransmitter that activates inhibitory glycine receptors and is a co-agonist for excitatory glutamatergic N-methyl-D-aspartate (NMDA) receptors. Two transporters, GLYT1 and GLYT2, regulate extracellular glycine concentrations within the CNS. Dysregulation of the extracellular glycine has been associated with hyperekplexia and nonketotic hyperglycinemia. Here, we report four individuals from two families who presented at birth with facial dysmorphism, encephalopathy, arthrogryposis, hypotonia progressing to hypertonicity with startle-like clonus, and respiratory failure. Only one individual survived the respiratory failure and was weaned off ventilation but has significant global developmental delay. Mildly elevated cerebrospinal fluid (CSF) glycine and normal serum glycine were observed in two individuals. In both families, we identified truncating mutations in SLC6A9, encoding GLYT1. We demonstrate that pharmacologic or genetic abolishment of GlyT1 activity in mice leads to mildly elevated glycine in the CSF but not in blood. Additionally, previously reported slc6a9-null mice and zebrafish mutants also display phenotypes consistent with the affected individuals we examined. Our data suggest that truncating SLC6A9 mutations lead to a distinct human neurological syndrome hallmarked by mildly elevated CSF glycine and normal serum glycine.


European Journal of Human Genetics | 2014

BRCA1/2 mutations and FMR1 alleles are randomly distributed: a case control study

Efrat Dagan; Yoram Cohen; Adi Mory; Vardit Adir; Zvi Borochowitz; Hila Raanani; Alina Kurolap; Svetlana Melikhan-Revzin; Dror Meirow; Ruth Gershoni-Baruch

BRCA mutation carriers were reported to display a skewed distribution of FMR1 genotypes, predominantly within the low normal range (CGG repeat number <26). This observation led to the interpretation that BRCA1/2 mutations are embryo-lethal, unless rescued by ‘low FMR1 alleles’. We undertook to re-explore the distribution of FMR1 alleles subdivided into low, normal and high (<26, 26–34, and >34 CGG repeats, respectively) subgenotypes, on a cohort of 125 Ashkenazi women, carriers of a BRCA1/2 founder mutation. Ashkenazi healthy females (n=368), tested in the frame of the Israeli screening population program, served as controls. BRCA1/2 carriers and controls demonstrated a comparable and non-skewed FMR1 subgenotype distribution. Taken together, using a homogeneous ethnic group of Ashkenazi BRCA1/2 mutation carriers, we could not confirm the reported association between FMR1 low genotypes and BRCA1/2 mutations. The notion that BRCA1/2 mutations are embryo-lethal unless rescued by the low FMR1 subgenotypes is hereby refuted.


Pediatric Pulmonology | 2014

Duplication in CHIT1 gene and the risk for Aspergillus lung disease in CF patients.

Galit Livnat; Ronen Bar-Yoseph; Adi Mory; Efrat Dagan; Nael Elias; Ruth Gershoni; Lea Bentur

Aspergillus often persists in the respiratory tract of patients with Cystic Fibrosis (CF) and may cause allergic broncho‐pulmonary aspergillosis (ABPA). Chitinases are enzymes that digest the chitin polymer. Plants use chitinase as a defense mechanism against fungi. Chitotriosidase (CHIT1) is the major chitinase in human airways. Variation in the coding region with 24‐bp duplication allele results in reduced CHIT1 activity. Recently, CHIT1 duplication heterozygocity was found in 6/6 patients with severe asthma and fungal sensitization (SAFS).

Collaboration


Dive into the Adi Mory's collaboration.

Top Co-Authors

Avatar

Alina Kurolap

Rambam Health Care Campus

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Amos Etzioni

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Hanna Mandel

Rambam Health Care Campus

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tamar Paperna

Rambam Health Care Campus

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hagit N. Baris

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge